The Effect of Ribomunyl and Licopid on Immunity Indexes in Gastric and Duodenal Ulcer
Dugina V.V., Shirali Rashmi, Babayan S.R., Lebedeva N.V., Rudakova G.V., Khrulyova N.S.
Key words: eradication, immunomodulators, H. Pylori contamination, Helicobacter pylori, gastric and duodenal ulcer, Т-lymphocytes.
2012,
issue 1,
page 75.
Full text
pdf
0
1590
The aim of the investigation is to study the effect of immunomodulators Ribomunyl and Licopidin on Helicobacter pylori eradication and cell-mediated immunity indexes in chronic gastric and duodenal ulcer.
Materials and methods. 30 patients with Helicobacter pylori associated gastric and duodenal ulcer were studied, and cell-mediated immunity indexes in 8 conditionally healthy persons were determined. The techniques used were endoscopic, cytomorphological and immunotechnique (indirect immunofluorescence using monoclonal antibodies to differentiation and activation antigen of lymphocytes) (LLC “Sorbent”, Moscow)). The intensity of H. pylori and T-lymphocyte subpopulation (CD4, CD8, CD16, CD95) contamination was determined to study the effect of immunomodulators on eradication and cell-mediated immunity.
Results. The administration of microbial immunomodulators — Ribomunyl and Licopidin — in combination with anti H. pylori therapy results in increasing H. Pylori eradication degree. These drugs have a positive effect on cell-mediated immunity indexes in patients with secondary immunodeficiency due to H. pylori contamination and antimicrobial therapy.
Conclusion. Ribomunyl and Licopidin can be recommended to be administered in combination with eradication scheme from the first day of Helicobacter pylori associated gastric and duodenal ulcer treatment.
- Aruin L.I., Kapuller L.L., Isakov V.A. Morfologicheskaya diagnostika bolezney zheludka i kishechnika [Morphological diagnosis of gastric and intestinal diseases]. Moscow: Triada-Kh; 2009; 483 p.
- Standarty diagnostiki i lecheniya kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevaniy (chetvertoe Moskovskoe soglashenie). Metodicheskie rekomendatsii №37 Departamenta zdravookhraneniya goroda Moskvy [Diagnostic and treatment standards of asid dependent and Helicobacter pylori associated diseases (the 4th Moscow Agreement). Cuidelines No.37 of Moscow Health Department]. Moscow: TsNIIG; 2010; 12 p.
- Zvyagintseva T.D., Ermolaev D.N. Ross Z Gastroenterol, gepatologii, koloproktologii 2002; 5(12): 26.
- Illek Ya.Yu., Bezus E.V., Suslova E.V. Uspekhi sovremennogo estestvoznaniya 2009; 1: 15–18.
- Nekrasov A.V. Immunol 2009; 1: 50–55.
- Pasechnikov V.D., Chukov S.Z. Klin Med 2000; 11: 9–12.
- Wilson K.T., Crabtree J.E. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007; 133: 288–308.
- Zambon C-F., Basso D., Navaglia F. et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1 V genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine 2007; 18: 242–251.
- Zambon C-F., Basso D., Navaglia F. Pro- and antiinflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005; 29(4): 141–152.
- Zhou W., Yamazaki S., Yamakawa A. et al. The diversity of vac A and cagA genes of Helicobacter pylori in East Asia. FEMS Immunol Med Microbiol 2010; 40: 81–87.
- Khaitov R.M., Pinegin B.V. Immunol 2003; 4: 196–203.
- Tsimmerman Ya.S., Mikhaleva E.N. Klin med 2003; 1: 40–44.
- Panayotopoulou E.G., Sgouras D.N., Papadakos K.S., Petraki K., Breurec S., Michopoulos S., Mantzaris G., Papatheodoridis G., Mentis A. CagA and VacA polymorphisms are associated with distinct pathological features in Helicobacter pylori-infected adults with peptic ulcer and non-peptic ulcer disease. J Clin Microbiol 2010 Jun; 48(6): 2237–2239.
- Pandey J.P., Frederick M. TNF-alpha, IL1-beta and immunoglobulin (GM and KM) gene polymorphisms in sarcoidosis. Hum Immunol 2002; 63(6): 485–491.
Dugina V.V., Shirali Rashmi, Babayan S.R., Lebedeva N.V., Rudakova G.V., Khrulyova N.S. The Effect of Ribomunyl and Licopid on Immunity Indexes in Gastric and Duodenal Ulcer.
Sovremennye tehnologii v medicine
2012; (1):
75